Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 8/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.73 |
| ▸ | LCK | P06239 | 1/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.73 |
| ▸ | RET | P07949 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | TEC | P42680 | 1/20 | 0.73 |
| ▸ | TXK | P42681 | 1/20 | 0.73 |
| ▸ | BLK | P51451 | 1/20 | 0.73 |
| ▸ | BMX | P51813 | 1/20 | 0.73 |
| ▸ | ITK | Q08881 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.73 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12070556 | 0.90 | BTK (0.82) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL9983654 | 0.89 | BTK (0.80) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL9984147 | 0.88 | BTK (0.79) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL12070603 | 0.88 | BTK (0.80) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL12071534 | 0.88 | BTK (0.78) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL19426950 | 0.88 | BTK (0.81) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL9983358 | 0.84 | BTK (0.73) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL29608300 | 0.84 | BTK (1.00) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL12064378 | 0.84 | BTK (1.00) | BTKJAK2NTRK1LCKLYN | |
| SCHEMBL9983880 | 0.83 | BTK (0.81) | BTKJAK2NTRK1LCKLYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-08 | — | — | US | disclosed |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-24 | — | — | US | disclosed |
| US-10106559-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2018-03-22 | — | — | US | disclosed |
| US-9850258-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850258-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170283438-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2014210085-A9 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2014210087-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| WO-2014210085-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-31 | — | — | WO | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2014-12-25 | — | — | US | disclosed |
| EP-2582668-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2013-04-18 | — | — | US | disclosed |
| WO-2011159857-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378475-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | BTK 1/4885JAK2 3/4885NTRK1 1870/4885 |
| US-20130096118-A1 | CARBOLINE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, PRKACA, CILK1 | BTK 1/4885JAK2 10/4885NTRK1 387/4885 |
| US-20180079758-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | BTK 1/4885JAK2 3/4885NTRK1 1870/4885 |
| US-20190023719-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | BTK 1/4885JAK2 3/4885NTRK1 1870/4885 |
| US-20170283438-A1 | SUBSTITUTED TETRAHYDROCARBAZOLE AND CARBAZOLE CARBOXAMIDE COMPOUNDS | BTK, CNKSR1, JAK2 | BTK 1/4885JAK2 3/4885NTRK1 1870/4885 |
| US-10106559-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BTK, CNKSR1, JAK2 | BTK 1/4885JAK2 3/4885NTRK1 1870/4885 |
| US-10435415-B2 | Substituted tetrahydrocarbazole and carbazole carboxamide compounds | BTK, CNKSR1, JAK2 | BTK 1/4885JAK2 3/4885NTRK1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.